Osteosarcoma over the age of forty

Grimer, R. J.; Cannon, Stephen R.; Taminiau, Antonie; Bielack, S.; Kempf-Bielack, Beate; Windhager, Reinhard; Dominkus, Martin; Sæter, Gunnar; Bauer, Henrik C. F.; Meller, I.; Szabó, Miklós; Follerås, Gunnar; San-Julián, Mikel; Eijken, J van der

doi:10.1016/s0959-8049(02)00478-1

Cited by 175 publications

(148 citation statements)

References 21 publications

Supporting

Mentioning

127

Contrasting

Order By: Relevance

“…A previous EMSOS study on 481 patients older than 40 years with localised skeletal osteosarcoma by Grimer [19] reported a 5-year OS of 46% similar to the 5-year OS of 51.4% reported in this study.…”

Section: Discussionsupporting

confidence: 86%

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients

Longhi

Bielack

Grimer

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 86%

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients

Longhi

Bielack

Grimer

et al. 2017

European Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…It is well known that older patients with osteosarcoma have more unfavorable prognosis [12] [13]. Our study also confirmed that 5-year OS and EFS rates were decreased as the patients' age were older (71.7% and 68.3% in ≤19 years old, 67.6% and 59.7% in 20 -40 years old, and 58.6% and 48.3% in ≥41 years old, respectively).…”

Section: Discussionsupporting

confidence: 86%

Is Osteosarcoma between the Two Peak Ages Different?

Chung¹,

Cho²,

Jeon³

et al. 2018

JCT

View full text Add to dashboard Cite

Background: Unlike two known peak age groups (10 -14 and older than 65 years of age), there was relatively scant attention in osteosarcoma patients between them, and previous reports had analyzed other than Asians. Therefore we conducted this study with Korean patients and focused on 20 -40 years of age, then investigated age-specific or race-specific meaningful outcomes. Materials and Methods: 379 patients who were newly diagnosed as osteosarcoma in two Korean major cancer hospitals from September 1986 to July 2015 with more than 2-year follow-up were retrospectively studied. There were 290 patients with 20 -40 years of age, 60 patients aged 19 or younger, and 29 patients aged 41 or older. Age at diagnosis, gender, location of primary lesion, metastasis at diagnosis, histologic subtypes, histologic response were analyzed as prognostic factors by overall survival (OS) and event-free survival (EFS) rates. Results: Primary pelvic lesion and poor histologic response were significantly unfavorable prognostic factors, but not age-specific. However, proportion of metastasis at diagnosis was significantly highest in 20 -40 years of age group. For the age at diagnosis, older patients presented poorer 5-year OS and EFS rates, but for 10-year, 20 -40 years of age group showed unusually better prognosis than younger age's, with statistic significance in OS rates but not in EFS rates. Conclusion: Osteosarcoma patients with 20 -40 years of age in Korea presented relatively better prognosis after longer-term 10-year despite their late diagnosis causing more metastasis at diagnosis, which emphasized expedite diagnosis and appropriate treatment to expect much better prognosis than peak age groups.

show abstract

“…Patients older than this often have medical comorbidities that may preclude an ideal dose of chemotherapy, reflected in a poorer overall survival [7,12]. Inclusion of the older cohort likely would have made the survival estimates smaller.…”

Section: Discussionmentioning

confidence: 99%

Conditional Survival Is Greater Than Overall Survival at Diagnosis in Patients With Osteosarcoma and Ewing’s Sarcoma

Miller

Lynch

Buckwalter

2013

Clinical Orthopaedics &Amp; Related Research

View full text Add to dashboard Cite

Background Conditional survival is a measure of the risk of mortality given that a patient has survived a defined period of time. These estimates are clinically helpful, but have not been reported previously for osteosarcoma or Ewing's sarcoma. Questions/purposes We determined the conditional survival of patients with osteosarcoma and Ewing's sarcoma given survival of 1 or more years. Methods We used the Surveillance, Epidemiology, and End Results (SEER) Program database to investigate cases of osteosarcoma and Ewing's sarcoma in patients younger than 40 years from 1973 to 2009. The SEER Program is managed by the National Cancer Institute and provides survival data gathered from population-based cancer registries. We used an actuarial life table analysis to determine any cancer cause-specific 5-year survival estimates conditional on 1 to 5 years of survival after diagnosis. We performed a similar analysis to determine 20-year survival from the time of diagnosis. Results The estimated 5-year survival improved each year after diagnosis. For local/regional osteosarcoma, the 5-year survival improved from 74.8% at baseline to 91.4% at 5 years-meaning that if a patient with localized osteosarcoma lives for 5 years, the chance of living for another 5 years is 91.4%. Similarly, the 5-year survivals for local/regional Ewing's sarcoma improved from 72.9% at baseline to 92.5% at 5 years, for metastatic osteosarcoma 35.5% at baseline to 85.4% at 5 years, and for metastatic Ewing's sarcoma 31.7% at baseline to 83.6% at 5 years. The likelihood of 20-year cause-specific survival from the time of diagnosis in osteosarcoma and Ewing's sarcoma was almost 90% or greater after 10 years of survival, suggesting that while most patients will remain disease-free indefinitely, some experience cancerrelated complications years after presumed eradication. Conclusions The 5-year survival estimates of osteosarcoma and Ewing's sarcoma improve with each additional year of patient survival. Knowledge of a changing risk profile is useful in counseling patients with time.

show abstract

Osteosarcoma over the age of forty

Cited by 175 publications

References 21 publications

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients

Extraskeletal osteosarcoma: A European Musculoskeletal Oncology Society study on 266 patients

Is Osteosarcoma between the Two Peak Ages Different?

Conditional Survival Is Greater Than Overall Survival at Diagnosis in Patients With Osteosarcoma and Ewing’s Sarcoma

Contact Info

Product

Resources

About